Sources
Loading...
Additional media
Loading...
DeepNewz, mobile.
People-sourced. AI-powered. Unbiased News.
Australia’s Mayne Pharma has filed a lawsuit against Indian drugmaker Sun Pharma over patent infringement. Despite the legal issues, Sun Pharma's stock has surged, reaching a 52-week high. On July 25, Sun Pharma’s stock hit ₹1,658 per share. The stock continued to rise, reaching an all-time high of ₹1,711.95 per share on July 26, soaring up to 2.80% on the BSE.
While Sun Pharma is facing patent infringement allegations from Melbourne-based Mayne Pharmaceuticals, it’s not been an issue for its investors. Sun Pharma’s stock reached a 52-week high recently, reaching ₹1,658 per share on July 25. Read more: https://t.co/LqsJdwFsbg
#MarketsWithBS | Sun Pharmaceutical's stock soared up to 2.80%, hitting all time high at 1711.95 per share on the BSE in Friday’s intraday trade. #SUNPHARMA #buzzingstocks #StockMarket https://t.co/VIXr7IWoep
Amid patent infringement allegations, Sun Pharma has seen a 52-week high surge in stock. The pharma giant’s legal issues do not seem to be a deterrent for investors at the moment. Read more: https://t.co/LqsJdwG00O
